The in vivo antitumor potential of Roy-Bz was thereafter evaluated using human tumor xenograft mouse models of control and PKCδ-knockdown HCT116 cells, following the same administration procedure conducted in the toxicological studies. This evidence concerns the gene PRKCD and neoplasm.